Global Myasthenia Gravis Market to reach USD 1.87 billion by 2027. Global Myasthenia Gravis Market is valued approximately USD 1 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.2% over the forecast period 2021-2027. Myasthenia gravis is a chronic autoimmune and neuromuscular disease that leads weakness in the skeletal muscles. The disease worsens when muscles are active and improves after rest. These affected muscles are responsible for breathing and moving arms, legs and other parts of the body.
Th growing adoption of immunotherapies used to relive the symptoms and problems associated with myasthenia gravis along with the regular approval of hopeful drugs and treatments of this disease are propelling the market of Myasthenia Gravis. The increasing awareness of rare diseases among people, coupled with the growth of biosimilars and biologics industry, are driving the Myasthenia Gravis market. There are no know causes of Myasthenia Gravis and it can target anyone. National Organization for Rare Diseases reports that autoimmune myasthenia gravis has a prevalence of approximately 14-40 per 100,000 individuals in the United States. It also states that estimated 10 percent of patients affected by this disease may develop potentially life-threatening complications due to severe involvement of muscles, including those used during breathing. Organization also observes autoimmune myasthenia gravis more often affects women than men. The lack of awareness and testing of this disease and mis-diagnosis of Myasthenia Gravis may act as a restraint for its growth. However, increasing efforts from government and private players to understand this disease through studies and research acts as an opportunity for Myasthenia Gravis Market in subsequent decade.

Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Myasthenia Gravis Market. Due to higher awareness for autoimmune diseases and their treatment as well as higher per capita income, North America has emerged as the significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit highest growth rate for the forecast period 2021-2027 owing to the growing diagnosis of the disease and better healthcare infrastructure. Rising disposable income and governmental push for the study of rare diseases will also boost growth in this region.

Major market player included in this report are:
Alexion Pharmaceutical Inc.
Grifols SA
Avadel Pharmaceuticals, Plc.
Novartis
Pfizer, Inc.
AbbVie Inc.
F.Hoffmann-La Roche AG
GlaxoSmithKline Plc.
Bausch Health Companies Inc.
Shire plc


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment:
Medication Market
Surgery Market
Others Market

By End-Use:
Hospitals Market
Clinics Market
Others Market

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Myasthenia Gravis Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors